![mRNA-encoded antibodies to combat SARS-CoV-2](https://epic.utoronto.ca/wp-content/uploads/2024/06/MM-Seminar-Laura-Walker-June-24-pdf.jpg)
![mRNA-encoded antibodies to combat SARS-CoV-2](https://epic.utoronto.ca/wp-content/uploads/2024/06/MM-Seminar-Laura-Walker-June-24-pdf.jpg)
Investigating the antibody response to SARS-CoV-2 after infection or vaccination
EPIC members Anne-Claude Gingras hosts the PhD public seminar for her PhD student Kento Abe.![EPIC Trainee Seminars](https://epic.utoronto.ca/wp-content/uploads/2023/11/Nov2023-seminar-1080x675.png)
EPIC Trainee Seminars
The monthly EPIC Trainee Seminars return for the 2023-24 year! These trainee-only seminars provide a safe and supportive environment for trainees to share their work, receive feedback from their peers and network. To sign up to present at a future seminar, please...![Tunnelling nanotube intercellular stealth infection in COVID-19 planned by 3CLpro main protease](https://epic.utoronto.ca/wp-content/uploads/2023/10/Overall-Nov7final-1080x675.jpg)
Tunnelling nanotube intercellular stealth infection in COVID-19 planned by 3CLpro main protease
Join EPIC member Samira Mubareka as she co-hosts Chris Overall from the University of British Columbia for a special seminar.![U of T researchers unveil new preclinical insights into why males are more likely to have severe COVID-19](https://epic.utoronto.ca/wp-content/uploads/2023/09/3I8A4494-scaled.jpg)
U of T researchers unveil new preclinical insights into why males are more likely to have severe COVID-19
A new study from a team of EPIC members has uncovered the biological reasons underlying sex differences in COVID-19 outcomes and is offering a promising new strategy to prevent illness. Early on during the pandemic, clinicians quickly noticed that males were more likely than females to be hospitalized or admitted to the ICU or to die from COVID-19 despite having similar infection rates. This pattern held true across all age groups and in countries around the world. The research, conducted in mice and published in the journal iScience, points to the ACE2 protein as a key contributor to differences in COVID-19 outcomes between males and females.